Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | XDH | P47989 | 3/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28736083 | 0.98 | CYP1A2 (0.52) | CYP1A2L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL7210200 | 0.82 | MAPK1 (0.50) | CYP1A2MAPK1RAB9ACYP2C9CDC7 | |
| SCHEMBL3576025 | 0.81 | MAPK1 (0.58) | CYP1A2ALDH1A1MAPK1CYP2C9AXL | |
| SCHEMBL4903170 | 0.81 | GSTP1 (0.48) | CYP1A2ALDH1A1KDM4EHPGDRAB9A | |
| SCHEMBL2354303 | 0.80 | MEN1 (0.46) | ALDH1A1KDM4EHPGDRAB9AKMT2A | |
| SCHEMBL7222934 | 0.80 | KDM4E (0.47) | ALDH1A1KDM4EHPGDHSD17B10MAPK1 | |
| SCHEMBL2349960 | 0.80 | XDH (0.53) | ALDH1A1KDM4ERAB9AKMT2AMEN1 | |
| SCHEMBL3480505 | 0.78 | PDE4B (0.37) | CYP1A2L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL4060637 | 0.77 | PTGS2 (0.41) | CYP1A2L3MBTL1ALDH1A1KDM4EHPGD | |
| SCHEMBL1003683 | 0.76 | TRPV3 (0.43) | CYP1A2ALDH1A1KDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114344306-B | Pharmaceutical composition containing phenylpyrimidinone hydrochloride, pharmaceutical preparation containing pharmaceutical composition, preparation method and application of pharmaceutical composition | 苏州旺山旺水生物医药有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-110256361-B | Bishydrazide compound containing phenylpyrimidinone structural fragment and preparation method thereof | 湖南人文科技学院 | 2023-06-16 | — | — | CN | claimed |
| EP-2383262-B1 | PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | TOPHARMAN SHANGHAI CO LTD (CN) | 2016-07-06 | — | — | EP | claimed |
| US-8871777-B2 | Phenylpyrimidone compounds, the pharmaceutical compositions, preparation methods and uses thereof | TOPHARMAN SHANGHAI CO., LTD. (CN) | 2014-10-28 | — | — | US | claimed |
| EP-2383262-A1 | PHENYL PYRIMIDONE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, PREPARATION METHODS AND USES THEREOF | Topharman Shanghai Co., Ltd. (CN) | 2011-11-02 | — | — | EP | claimed |
| EP-1562602-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | Vivus, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20050009835-A1 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | THOMAS THOMAS NADACKAL (US) | 2005-01-13 | — | — | US | claimed |
| EP-1418896-A2 | ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF PREMATURE EJACULATION | Vivus, Inc. (US) | 2004-05-19 | — | — | EP | claimed |
| WO-2004037262-A2 | IMMEDIATE RELEASE TOPICAL PHARMACEUTICAL FORMULATION FOR ENHANCEMENT OF FEMALE SEXUAL DESIRE AND RESPONSIVENESS | VIVUS, INC. (US) | 2004-05-06 | — | — | WO | claimed |
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PFIZER INC | 2004-05-06 | — | — | US | claimed |
| WO-2001041807-A2 | TRANSMUCOSAL COMPOSITION CONTAINING A PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 2001-06-14 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| EP-0793486-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Pfizer Limited (GB) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016644-A1 | cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | PFIZER LIMITED (GB) | 1996-06-06 | — | — | WO | claimed |
| EP-0126296-B1 | SUBSTITUTED PHENYL-2-(1H)-PYRIMIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE, AND PREPARATIONS CONTAINING THESE COMPOUNDS | Beiersdorf Aktiengesellschaft (DE) | 1988-06-01 | — | — | EP | claimed |
| US-4582834-A | INOTROPIC AGENTS | BEIERSDORF AKTIENGESELLSCHAFT (DE) | 1986-04-15 | — | — | US | claimed |
| EP-0126296-A1 | Substituted phenyl-2-(1H)-pyrimidinones, process for their preparation and their use, and preparations containing these compounds | Beiersdorf Aktiengesellschaft (DE) | 1984-11-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087599-A1 | cGMP-PDE inhibitors for the treatment of erectile dysfunction | PDE3A, PDE5A, PDE2A | CYP1A2 536/4885L3MBTL1 2629/4885ALDH1A1 412/4885 |
| US-20050009835-A1 | Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors | PDE3A, PDE3B, PDE5A | CYP1A2 507/4885L3MBTL1 3210/4885ALDH1A1 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.